 Proactive Investors USA & Canada | Cell Therapeutics Announces European Launch Of Pixuvri® For Treatment Of ... Sacramento Bee The European Medicines Agency's (the "EMA") Committee for Medicinal Products for Human Use has accepted PIX306, CTI's ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who ... Cell Therapeutics shares surge on commercial launch of lymphoma drug in ... Before Jumping on the Cell Therapeutics (CTIC) Bandwagon (CELG, CTIC ... |
